HK1146055A1 - Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators - Google Patents

Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators

Info

Publication number
HK1146055A1
HK1146055A1 HK11100256.6A HK11100256A HK1146055A1 HK 1146055 A1 HK1146055 A1 HK 1146055A1 HK 11100256 A HK11100256 A HK 11100256A HK 1146055 A1 HK1146055 A1 HK 1146055A1
Authority
HK
Hong Kong
Prior art keywords
histamine
phenyl
substituted
therapeutic use
receptor modulators
Prior art date
Application number
HK11100256.6A
Other languages
English (en)
Inventor
Werngard Czechtizky
Zhongli Gao
William J Hurst
Lothar Schwink
Siegfried Stengelin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1146055A1 publication Critical patent/HK1146055A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
HK11100256.6A 2007-10-17 2011-01-12 Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators HK1146055A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98060207P 2007-10-17 2007-10-17
PCT/US2008/079758 WO2009052063A1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators

Publications (1)

Publication Number Publication Date
HK1146055A1 true HK1146055A1 (en) 2011-05-13

Family

ID=40137955

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100256.6A HK1146055A1 (en) 2007-10-17 2011-01-12 Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators

Country Status (20)

Country Link
US (1) US8227504B2 (da)
EP (1) EP2205558B1 (da)
JP (1) JP5377504B2 (da)
KR (1) KR20100092443A (da)
CN (1) CN101903342B (da)
AU (1) AU2008312636B2 (da)
BR (1) BRPI0818766A2 (da)
CA (1) CA2702834C (da)
DK (1) DK2205558T3 (da)
ES (1) ES2392122T3 (da)
HK (1) HK1146055A1 (da)
IL (1) IL205000A0 (da)
MA (1) MA31857B1 (da)
MX (1) MX2010004003A (da)
MY (1) MY150210A (da)
NZ (1) NZ584691A (da)
PT (1) PT2205558E (da)
RU (1) RU2477721C2 (da)
WO (1) WO2009052063A1 (da)
ZA (1) ZA201002113B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702467C (en) 2007-10-17 2012-11-27 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
RU2477719C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение
DK2215058T3 (da) 2007-10-17 2012-03-12 Sanofi Sa Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
AR074466A1 (es) * 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
TW201202251A (en) 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
AR081383A1 (es) 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
JP5784110B2 (ja) 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
AR081498A1 (es) 2010-05-11 2012-09-19 Sanofi Aventis Derivados de n-alquil -y n-acil-tetrahidroisoquinolina sustituidos, preparacion y su uso terapeutico de los mismos
AR081382A1 (es) * 2010-05-11 2012-08-29 Sanofi Aventis Derivados de n-heterocicloalquil bipirrolidinilfenil amida sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central.
RU2562461C1 (ru) * 2014-04-30 2015-09-10 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Спин-меченое производное кинуренина и способ его получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
CA2504272A1 (en) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
JP5052497B2 (ja) * 2005-03-17 2012-10-17 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体アンタゴニストとしてのピロリジン誘導体
CN101151244B (zh) * 2005-04-01 2014-09-03 伊莱利利公司 组胺h3受体活性剂、制备和治疗用途
WO2007005503A1 (en) * 2005-07-01 2007-01-11 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
AU2006308167A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
TW200800908A (en) * 2006-02-15 2008-01-01 Sanofi Aventis Novel azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CA2702467C (en) 2007-10-17 2012-11-27 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
RU2477719C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение
DK2215058T3 (da) 2007-10-17 2012-03-12 Sanofi Sa Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf

Also Published As

Publication number Publication date
EP2205558B1 (en) 2012-07-25
PT2205558E (pt) 2012-11-02
AU2008312636A1 (en) 2009-04-23
JP5377504B2 (ja) 2013-12-25
CN101903342B (zh) 2012-11-21
MY150210A (en) 2013-12-13
EP2205558A1 (en) 2010-07-14
DK2205558T3 (da) 2012-11-05
RU2477721C2 (ru) 2013-03-20
CA2702834C (en) 2013-01-15
RU2010119530A (ru) 2011-11-27
KR20100092443A (ko) 2010-08-20
AU2008312636B2 (en) 2013-03-14
CN101903342A (zh) 2010-12-01
IL205000A0 (en) 2010-11-30
CA2702834A1 (en) 2009-04-23
US8227504B2 (en) 2012-07-24
NZ584691A (en) 2011-09-30
BRPI0818766A2 (pt) 2015-04-14
WO2009052063A1 (en) 2009-04-23
ES2392122T3 (es) 2012-12-04
US20100173898A1 (en) 2010-07-08
JP2011500694A (ja) 2011-01-06
MA31857B1 (fr) 2010-11-01
ZA201002113B (en) 2010-12-29
MX2010004003A (es) 2010-04-30

Similar Documents

Publication Publication Date Title
HK1146055A1 (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
EP2150109A4 (en) PHARMACEUTICAL USE OF SUBSTITUTED AMIDES
GB0719803D0 (en) Therapeutic compounds and their use
HK1211889A1 (en) Therapeutic use of diaminophenothiazines
GB0719644D0 (en) Therapeutic compounds and their use
GB0803018D0 (en) Therapeutic compounds and their use
GB0804685D0 (en) Therapeutic compounds and their use
IL190110A0 (en) Cyclopropyl amines as modulators of the histamine h3 receptor
GB0724251D0 (en) Therapeutic compounds and their use
IL211694A0 (en) Use of-anti-connexin agents for modulating the therapeutic effect of psychotropic drugs
GB0722680D0 (en) Therapeutic compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
IL195514A0 (en) Substituted pyridiyl amide compounds as modulators of the histamine h3 receptor
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0710981D0 (en) New Therapeutic use
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
GB0812913D0 (en) Therapeutic compounds and their use
EP2273266A4 (en) PARASPORIN-1 RECEPTOR AND USE THEREOF
GB0802128D0 (en) Therapeutic compounds and their use
GB0808690D0 (en) Therapeutic use
GB0705517D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use
GB0807710D0 (en) Receptor and modulators thereof
GB0821539D0 (en) Therapeutic compounds and their use
GB0709494D0 (en) Therapeutic use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161014